Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $5.47 Million Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its position in Becton, Dickinson and Company (NYSE:BDX) by 135.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 22,936 shares of the medical instruments supplier’s stock after purchasing an additional 13,186 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Becton, Dickinson and Company were worth $5,473,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Ameriprise Financial Inc. boosted its stake in Becton, Dickinson and Company by 6.4% during the second quarter. Ameriprise Financial Inc. now owns 5,055,354 shares of the medical instruments supplier’s stock worth $1,181,483,000 after acquiring an additional 302,893 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Becton, Dickinson and Company by 1.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 4,905,114 shares of the medical instruments supplier’s stock worth $1,146,374,000 after acquiring an additional 87,230 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Becton, Dickinson and Company by 8.5% in the second quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock valued at $1,031,167,000 after buying an additional 346,720 shares in the last quarter. Clearbridge Investments LLC lifted its stake in shares of Becton, Dickinson and Company by 3.1% in the second quarter. Clearbridge Investments LLC now owns 2,984,524 shares of the medical instruments supplier’s stock valued at $697,513,000 after buying an additional 89,157 shares in the last quarter. Finally, First Eagle Investment Management LLC lifted its stake in shares of Becton, Dickinson and Company by 32.5% in the second quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock valued at $655,149,000 after buying an additional 688,296 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

BDX has been the subject of several analyst reports. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Evercore ISI lifted their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Raymond James lowered their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Finally, Stifel Nicolaus boosted their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $282.63.

Becton, Dickinson and Company Price Performance

BDX stock traded down $0.27 during midday trading on Wednesday, reaching $237.24. The company had a trading volume of 38,746 shares, compared to its average volume of 1,368,090. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $259.92. The company has a market capitalization of $68.56 billion, a P/E ratio of 52.31, a P/E/G ratio of 1.79 and a beta of 0.42. The firm has a 50-day moving average price of $237.58 and a 200-day moving average price of $235.04.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The company had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. During the same quarter in the prior year, the company earned $2.96 EPS. The firm’s revenue was up 2.3% on a year-over-year basis. On average, research analysts anticipate that Becton, Dickinson and Company will post 13.11 earnings per share for the current fiscal year.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.